V souladu s legislativou České republiky poskytuje Společnost služby pouze kvalifikovaným investorům!

Achilles Therapeutics (ACHL) FINANCIAL RESULTS FOR SECOND QUARTER 2022.

Start-ups and IPO

09.08.2022

Non-GAAP net loss per share for the second quarter of 2022 was -0.44 dollars.

Cash and cash equivalents amounted to $201.6 million in the second quarter.

Achilles Therapeutics (ACHL) FINANCIAL RESULTS FOR SECOND QUARTER 2022.

Categories